ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune checkpoint inhibitors (ICIs) are highly effective cancer therapies. However, they are associated with considerable adverse cardiovascular (CV) outcomes. We investigated the risk factors for CV hospitalisations and all-cause mortality in oncology patients receiving ICIs.
methodsA retrospective cohort study of adult patients administered ICIs between 1st January 2010 and 1st January 2020 in New South Wales, Australia. Electronic medical records were accessed to obtain demographic and clinical data. Univariate analysis included Chi-squared test for categorical variables and Student's t-test for continuous variables. Binary logistic regression was used for multivariate analysis. Mortality was analysed using Cox regression including (i) time-dependent Cox models with CV admission as a time-varying covariate and (ii) a 1-year landmark sensitivity analysis.
resultsOut of 1,080 patients receiving ICIs during the study period, 340 patients (31.5%) had at least one CV hospital admission, and 763 patients (70.6%) had died by the end of the follow-up period. On multivariable analysis, prior history of heart failure and/or cardiomyopathy (p < 0.001), arrhythmia (p < 0.001) and ischaemic heart disease (p < 0.001) were independently associated with an increased risk of CV hospital admission by approximately fourfold, while CV hospitalisation during follow-up (p < 0.001) was independently associated with an increased risk of all-cause mortality. In a time-dependent Cox model (n = 928; excluding CV admissions with missing admission timing), CV admission was associated with higher subsequent mortality (HR 3.29 [95% CI 2.70-4.02]; p < 0.001). In a 1-year landmark sensitivity analysis among patients alive at 365 days (n = 533), CV admission within 1 year was associated with higher subsequent mortality (HR 2.36 [95% CI 1.61-3.45]; p < 0.001).
conclusionIn cancer patients treated with ICIs, pre-existing CV risk factors significantly increase the risk of CV hospitalisations and all-cause mortality. Appropriate CV risk monitoring and management should be considered for people with cancer receiving ICI therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.